Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Associations of the COMT Val158Met Polymorphism with Risk of Endometrial and Ovarian Cancer: a Pooled Analysis of Case-control Studies

  • Liu, Jin-Xin (Department of Oncology, Longgang District Central Hospital of ShenZhen) ;
  • Luo, Rong-Cheng (Department of Oncology, TCM-Integrated Hospital, Southern Medical University) ;
  • Li, Rong (Department of Oncology, Nanfang Hospital) ;
  • Li, Xia (Department of Oncology, Longgang District Central Hospital of ShenZhen) ;
  • Guo, Yu-Wu (Department of Oncology, Longgang District Central Hospital of ShenZhen) ;
  • Ding, Da-Peng (Institute of Genetic Engineering, Southern Medical University) ;
  • Chen, Yi-Zhi (Department of Health Records, Longgang District Central Hospital of ShenZhen)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

This meta-analysis was conducted to examine whether the genotype status of Val158Met polymorphism in catechol-O-methyltransferase (COMT) is associated with endometrial and ovarian cancer risk. Eligible studies were identified by searching several databases for relevant reports published before January 1, 2014. Pooled odds ratios (ORs) were appropriately derived from fixed-effects or random-effects models. In total, 15 studies (1,293 cases and 2,647 controls for ovarian cancer and 2,174 cases and 2,699 controls for endometrial cancer) were included in the present meta-analysis. When all studies were pooled into the meta-analysis, there was no evidence for significant association between COMT Val158Met polymorphism and ovarian cancer risk (Val/Met versus Val/Val: OR=0.91, 95% CI=0.76-1.08; Met/Met versus Val/Val: OR=0.90, 95% CI=0.73-1.10; dominant model: OR=0.90, 95% CI=0.77-1.06; recessive model: OR=0.95, 95% CI=0.80-1.13). Similarly, no associations were found in all comparisons for endometrial cancer (Val/Met versus Val/Val: OR 0.97, 95% CI=0.77-1.21; Met/Met versus Val/Val: OR=1.02, 95% CI=0.73-1.42; dominant model: OR=0.98, 95% CI=0.77-1.25; recessive model: OR=1.02, 95% CI=0.87-1.20). In the subgroup analyses by source of control and ethnicity, no significant associations were found in any subgroup of population. This meta-analysis strongly suggests that COMT Val158Met polymorphism is not associated with increased endometrial and ovarian cancer risk.

Keywords

References

  1. Axelrod J, Tomchick R (1958). Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem, 233, 702-5.
  2. Chang I, Liu J, Majid S, et al (2012). Catechol-O-methyltransferasemediated metabolism of 4-hydroxyestradiol inhibits the growth of human renal cancer cells through the apoptotic pathway. Carcinogenesis, 33, 420-6. https://doi.org/10.1093/carcin/bgr294
  3. Dawling S, Roodi N, Mernaugh RL, Wang X, and Parl FF (2001). Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens, comparison of wild-type and variant COMT isoforms. Cancer Res, 61, 6716-22.
  4. Delort L, Chalabi N, Satih S, et al (2008). Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res, 28, 3079-81.
  5. DeMille MM, Kidd JR, Ruggeri V, et al (2002). Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum Genet, 111, 521-37. https://doi.org/10.1007/s00439-002-0809-0
  6. Doherty JA, Weiss NS, Freeman RJ, et al (2005). Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev, 14, 357-66. https://doi.org/10.1158/1055-9965.EPI-04-0479
  7. Garner EI, Stokes EE, Berkowitz RS, et al (2002). Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-Omethyltransferase and risk of epithelial ovarian cancer. Cancer Res, 62, 3058-62.
  8. Goodman JE, Lavigne JA, Hengstler JG, et al (2000). Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk. Cancer Epidemiol Biomarkers Prev, 9, 1373-6.
  9. Goodman MT, McDuffie K, Kolonel LN, et al (2001). Casecontrol study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev, 10, 209-16.
  10. Hennessy BT, Coleman RL, Markman M (2009). Ovarian cancer. Lancet, 374, 1371-82. https://doi.org/10.1016/S0140-6736(09)61338-6
  11. Hirata H, Hinoda Y, Okayama N, et al (2008). COMT polymorphisms affecting protein expression are risk factors for endometrial cancer. Mol Carcinog, 47, 768-74. https://doi.org/10.1002/mc.20432
  12. Holt SK, Rossing MA, Malone KE, et al (2007). Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev, 16, 481-9. https://doi.org/10.1158/1055-9965.EPI-06-0831
  13. Jakubowska A, Gronwald J, Menkiszak J, et al (2010). BRCA1-associated breast and ovarian cancer risks in Poland, no association with commonly studied polymorphisms. Breast Cancer Res Treat, 119, 201-11. https://doi.org/10.1007/s10549-009-0390-5
  14. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  15. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  16. Lachman HM, Papolos DF, Saito T, et al (1996). Human catechol-O-methyltransferase pharmacogenetics, description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6, 243-50. https://doi.org/10.1097/00008571-199606000-00007
  17. Lajin B, Hamzeh AR, Ghabreau L, et al (2013). Catechol-Omethyltransferase Val 108/158 Met polymorphism and breast cancer risk: a case control study in Syria. Breast Cancer, 20, 62-6. https://doi.org/10.1007/s12282-011-0309-y
  18. Lundin E, Wirgin I, Lukanova A, et al (2012). Selected polymorphisms in sex hormone-related genes, circulating sex hormones and risk of endometrial cancer. Cancer Epidemiol, 36, 445-52. https://doi.org/10.1016/j.canep.2012.04.006
  19. McGrath M, Hankinson SE, Arbeitman L, et al (2004). Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis, 25, 559-65.
  20. Millikan RC, Pittman GS, Tse CK, et al (1998). Catechol-Omethyltransferase and breast cancer risk. Carcinogenesis, 19, 1943-7. https://doi.org/10.1093/carcin/19.11.1943
  21. Ortashi O (2013). Gynecological cancer services in Arab countries: present scenario, problems and suggested solutions. Asian Pac J Cancer Prev, 14, 2147-50. https://doi.org/10.7314/APJCP.2013.14.3.2147
  22. Park BL, Shin HD, Cheong HS, et al (2009). Association analysis of COMT polymorphisms with schizophrenia and smooth pursuit eye movement abnormality. J Hum Genet, 54, 709-12. https://doi.org/10.1038/jhg.2009.102
  23. Sellers TA, Schildkraut JM, Pankratz VS, et al (2005). Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev, 14, 2536-43. https://doi.org/10.1158/1055-9965.EPI-05-0142
  24. Szyllo K, Smolarz B, Romanowicz-Makowska H, et al (2007). The risk of endometrial cancer appearance and CYP19 and COMT gene polymorphism. Pol Merkur Lekarski, 22, 208-10.
  25. Tao MH, Cai Q, Xu WH, et al (2006). Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev, 15, 2570-3. https://doi.org/10.1158/1055-9965.EPI-06-0498
  26. Thompson PA, Shields PG, Freudenheim JL, et al (1998). Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res, 58, 2107-10.
  27. Wang SS, Morton LM, Bergen AW, et al (2007). Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Hum Genet, 122, 41-9. https://doi.org/10.1007/s00439-007-0374-7
  28. Yuzhalin AE, Kutikhin AG (2012). ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia. Asian Pac J Cancer Prev, 13, 5091-6. https://doi.org/10.7314/APJCP.2012.13.10.5091
  29. Zhao XM, Xie MQ, Yang DZ, et al (2007). Polymorphism of catechol-O-methyltransferase gene in relation to the risk of endometrial cancer. Zhonghua Fu Chan Ke Za Zhi, 42, 116-9.
  30. Zimarina TC, Kristensen VN, Imianitov EN, and Bershtein LM (2004). Polymorphisms of CYP1B1 and COMT in breast and endometrial cancer. Mol Biol, 38, 386-93.

Cited by

  1. The Val158Met polymorphism in COMT gene and cancer risk: role of endogenous and exogenous catechols vol.49, pp.1, 2017, https://doi.org/10.1080/03602532.2016.1258075